J&J: Study Shows Value of Mix-and-Match Approach With Booster

Johnson & Johnson says preliminary results from an independent study showed that a booster shot of its Covid-19 vaccine administered six months after a two-dose primary regimen of Pfizer-BioNTech’s vaccine raised both antibody and T-cell responses.

• Study was conducted by Beth Israel Deaconess Medical Center but included a subset of participants from a study sponsored by its subsidiary Janssen
• Johnson & Johnson says findings reinforce a study published in The Lancet showing showing a mix-and-match booster

To view the source of this information click here

To contact the reporter on this story:
Sebastian Tong in San Francisco at stong41@bloomberg.net

To ...